Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2012

View Archived Issues

New approach for the rational and automated design of ligands against multiple drug targets

Sunovion Pharmaceuticals synthesizes new mGlu5 receptor modulators

Neuren Pharmaceuticals to conduct phase II trial of NNZ-2566 in Rett syndrome

U.K. researchers develop novel model of B-cell and myeloid malignancies

Forest and Glenmark to develop agents for chronic inflammatory conditions

Takeda and Amylin terminate worldwide agreement

AMAG Pharmaceuticals files sNDA for Feraheme

Favorable results presented for BC-2059, a novel beta-catenin inhibitor

NewGen Therapeutics discloses novel PARP-1 inhibitors

Japanese researchers patent new insulin secretagogues

Infinity Pharmaceuticals amends license agreement with Millennium

Daiichi Sankyo synthesizes new series of renin inhibitors

Covidien to acquire CV Ingenuity

Bristol-Myers Squibb prepares novel Abeta production inhibitors

Clinical trial notification accepted in Japan for phase I oral rigosertib trial

Study of voclosporin in uveitis does not meet primary endpoint

Ajinomoto Pharmaceuticals and Yoshindo to form joint venture

Otsuka obtains new approvals for carnitine deficiency treatments

Pfizer and Bristol-Myers Squibb obtain Japanese approval for novel anticoagulant

Neupro Patch approved in Japan for Parkinson's disease and restless legs syndrome

Japanese MHLW approves marketing application for Cimzia in RA

Japanese MHLW approves Novo Nordisk's combination therapy for diabetes

ABT-199 demonstrates antitumor activity in patients with NHL

Addex Therapeutics characterizes novel mGlu7 negative allosteric modulator

German researchers develop novel technique to study MM cell engraftment and progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...